Shares of Ampio Pharmaceuticals (NYSEMKT: AMPE) are on the rise after the company released a positive second-quarter earnings report this morning. News of progress with the company's experimental COVID-19 treatment, Ampion, pushed the stock 17.5% higher as of 1:06 p.m. on Thursday.
This clinical-stage drugmaker didn't have any product revenue to report, but progress with an experimental COVID-19 treatment encouraged investors to drive the stock higher. After losing $3.6 million during the second quarter, Ampio Pharmaceuticals finished June with $20.5 million in cash on its balance sheet.
Image source: Getty Images.
For further details see:
Here's Why Ampio Pharmaceuticals Stock Is Surging Today